MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 224,600 shares, a growth of 19.3% from the August 31st total of 188,200 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 39,300 shares, the days-to-cover ratio is currently 5.7 days.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on MediciNova in a research note on Saturday. They issued a “hold” rating for the company.
Read Our Latest Report on MNOV
MediciNova Stock Performance
MediciNova (NASDAQ:MNOV – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, equities research analysts expect that MediciNova will post -0.23 EPS for the current fiscal year.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
- Five stocks we like better than MediciNova
- What Are Growth Stocks and Investing in Them
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Ride Out The Recession With These Dividend Kings
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Market Cap Calculator: How to Calculate Market Cap
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.